Basiliximab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IL2RA/CD25, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. A recombinant chimeric (murine/human) monoclonal antibody (IgG1k) that functions as an immunosuppressive agent, specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2R alpha, also known as CD25 antigen) on the surface of activated T-lymphocytes. It is a 144 kDa glycoprotein obtained from fermentation of an established mouse myeloma cell line genetically engineered to express plasmids containing the human heavy and light chain constant region genes and mouse heavy and light chain variable region genes encoding the RFT5 antibody that binds selectively to the IL-2R alpha. Basiliximab binds with high-affinity to the alpha-subunit (CD25) of the high-affinity IL-2 receptor. This inhibits IL-2 binding, which inhibits T-cell activation and prevents the body from mounting an immune response against the foreign kidney.
Target
IL2RA/CD25
Research Area
Chimeric Monoclonal Antibodies, Biosimilars
Clonality
Monoclonal
Reactivity
Human
Expression
Recombinant
Tested Applications
ELISA
Host
Human, Mouse
Recommended dilutions
Optimal dilutions/concentrations should be determined by the end user.
Conjugation
Unconjugated
Isotype
IgG1 Kappa
Form
Liquid
Purity
> 95%
Purification
Purified from cell culture supernatants by Protein A/G chromatography.
Storage
Store at 4°C for up to 2 weeks. Aliquot and store at -20°C for long term storage. Avoid repeated freeze/thaw cycles.
Shelf Life
12 months.
Buffer
0.01 M PBS, pH 7.4.
CAS Number
179045-86-4
Concentration
Batch-dependent, typically between 0.5-2.0 mg/ml.
Availability
Shipped within 5-10 working days.
Note
THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION.
We use cookies necessary for the function of our website, to improve your experience, analyse our traffic, and cookies that optimise the performance. To learn more about our cookies, please read our Cookie Notice.